The position the Company aspires to establish by FY2033 is to become a company that strongly turns the “value creation cycle” and continuously translates innovation into real-world solutions focusing on disease fields in oncology, psychiatry & neurology and others, and on modalities such as small molecules and regenerative medicine/cell therapy. By turning the value creation cycle, the Company will strategically deepen and expand these strengths as well as establish a distinctive global presence in order to contribute to the betterment of healthcare and fuller lives of people worldwide.


Important Notice
Showcase Sumitomo Pharma in a nutshell
Here you can search for the strengths of Sumitomo Pharma’s business, Sumitomo Pharma’s initiatives, and other information that interests you by selecting tags.
-
Integrated Report 2025
-
Message from the President
- Profile
-
About Sumitomo Pharma
- Profile
-
Video / Ad Library
- Profile
-
Official Facebook page
- Profile
-
Reboot 2027
- Profile
-
iPS Cell-Derived Product Transportation Project
- Others
-
Sumitomo Pharma’s DX
- DX
-
Philosophy
- Profile
No results were found matching your search.
Strengths Sumitomo Pharma’s Three Strengths
- 1R&D Capabilities
- 2Human Resources
- 3Global Business Platforms
Press Releases
- Nov. 07, 2025 Posted Conference on Q2 FY2025 Financial Results [Webcast] Finances
- Nov. 04, 2025 Sumitomo Pharma America to Present New Investigational Data at the 2025 American Society of Hematology Annual Meeting(PDF/81KB) R&D
- Oct. 31, 2025 Presentation Material (Conference on Q2 FY2025 Financial Results)(PDF/688KB) Finances
- Oct. 31, 2025 Supplementary Financial Data (IFRS) for the Second Quarter of the Year Ending March 31, 2026(PDF/270KB) Finances
- Oct. 31, 2025 Summary of Consolidated Financial Results for the Second Quarter (First Half) of the Year Ending March 31, 2026 [IFRS](PDF/464KB) Finances
Notices
- Oct. 21, 2025 Posted Integrated Report 2025 Others
- Sep. 30, 2025 Japan Airlines Featured Our iPS Cell-Derived Product Transportation Project on Their Website. Others
- Jun. 30, 2025 Consolidated Financial Statements for Years ended March 31, 2025 and 2024 Finances
For the Press
Our latest press releases and other information for members of the press,
including various data sets and guidelines for their use.
-
Sustainability
Sumitomo Pharma defines the practice of its Mission, “To broadly contribute to society through value creation based on innovative research and development activities for the betterment of healthcare and fuller lives of people worldwide,” as Sustainability Management. To this end , Sumitomo Pharma is pursuing Sustainability Management through a variety of initiatives, including the development of innovative products and healthcare solutions, and contribution to the development of science.
-
About Us
Message from the President, corporate profile of Sumitomo Pharma, business activities, mid-term management plan, key locations and group companies, etc.
-
Investor Relations
Information for shareholders and investors of Sumitomo Pharma, including management policies, IR materials, and stock and shareholder-related information.


